Immune cells from donors show promise against Hard-to-Treat lymphoma
Disease control
Completed
This study tested an experimental therapy called AB-101, made from donor natural killer (NK) cells, in 45 people with B-cell non-Hodgkin lymphoma that returned or didn't respond to prior treatments. The goal was to see if AB-101 is safe and can shrink tumors when given alone or c…
Phase: PHASE1, PHASE2 • Sponsor: Artiva Biotherapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC